Charles Harrington

Dr. Charles Harrington is a Senior Research Fellow at the University of Aberdeen's School of Medicine, Medical Sciences and Nutrition. With a background in microbiology, he has transitioned to become a leading researcher in neurodegenerative diseases, particularly focusing on Alzheimer's disease and tau protein biology. His career spans over four decades, with significant contributions to understanding the molecular mechanisms of protein aggregation in neurodegenerative conditions.

• BSc (Hons) Microbiology, University of Glasgow (1977)
• PhD Microbiology, University of Glasgow (1980)

Harrington's research interests center on the biology of tau protein in aging and Alzheimer's disease, with emphasis on diseases characterized by protein aggregation and methods to prevent these processes. His work has evolved from early studies on microbial cell walls to current investigations of tau pathology, demonstrating remarkable interdisciplinary expertise. He has developed assays for screening tau aggregation inhibitors and has extensively studied the therapeutic potential of hydromethylthionine.

Analysis of his recent publications (2021-2025) reveals a strong focus on tau protein aggregation mechanisms, neuroinflammation, synaptic dysfunction in neurodegenerative diseases, and the therapeutic effects of tau aggregation inhibitors. His work frequently examines interactions between different therapeutic approaches, particularly how cholinesterase inhibitors might interfere with tau-targeting treatments. Harrington's research bridges molecular mechanisms with clinical applications, contributing significantly to the development of biomarkers and therapeutic strategies for Alzheimer's disease and related tauopathies.

As Chief Scientific Officer for TauRx Therapeutics Ltd, Harrington oversees non-clinical activities for a company conducting phase 3 trials of hydromethylthionine. His collaborative work spans multiple international institutions, with numerous co-authors across neuroscience, biochemistry, and clinical research fields. While specific grant information isn't detailed in the provided text, his extensive publication record suggests substantial research funding support over his career.

Harrington's laboratory work appears focused on tau transgenic mouse models, particularly investigating how tau pathology affects synaptic function, neurotransmitter systems, and behavioral outcomes. His research team has developed sophisticated methods for studying protein aggregation and its consequences in neurodegenerative disease models.